Format

Send to

Choose Destination
Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Author information

1
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
2
Department of Medicine, University of California at San Diego, San Diego, California.
3
Department of Otolaryngology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
4
Department of Medicine, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
5
Department of Radiation Oncology, Duke Cancer Institute, Durham, North Carolina.
6
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
7
Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
8
Department of Radiation Oncology, Yale Cancer Center, New Haven, Connecticut.
9
Department of Surgery, Ohio State University, Columbus, Ohio.
10
Department of Medicine, University of Washington, Seattle, Washington.
11
Department of Immunology, Earle A. Chiles Research Institute, Portland, Oregon.
12
Deparment of Medicine, University of Chicago, Chicago, Illinois.
13
Department of Internal Medicine, Ohio State University, Columbus, Ohio.
14
Center for Cancer Research, Bethesda, Maryland.
15
Department of Radiation Oncology-Radiation Therapy, Stanford University, Stanford, California.
16
Department of Radiation Oncology, University of Colorado, Aurora, Colorado.
17
Department of Otolaryngology, University of Maryland, Baltimore, Maryland.
18
Cancer Therapeutics Evaluation Program.

Abstract

Recent advances have permitted successful therapeutic targeting of the immune system in head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets and agents are being rapidly adopted by the oncologic community and hold considerable promise. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issue of how to further investigate the use of immunotherapy in patients with HNSCC. The goals of the meeting were to consider phase 2 or 3 trial designs primarily in 3 different patient populations: those with previously untreated, human papillomavirus-initiated oropharyngeal cancers; those with previously untreated, human papillomavirus-negative HNSCC; and those with recurrent/metastatic HNSCC. In addition, a separate committee was formed to develop integrative biomarkers for the clinical trials. The meeting started with an overview of key immune components and principles related to HNSCC, including immunosurveillance and immune escape. Four clinical trial concepts were developed at the meeting integrating different immunotherapies with existing standards of care. These designs were presented for implementation by the head and neck committees of the National Cancer Institute-funded National Clinical Trials Network. This article summarizes the proceedings of this Clinical Trials Planning Meeting, the purpose of which was to facilitate the rigorous development and design of randomized phase 2 and 3 immunotherapeutic trials in patients with HNSCC. Although reviews usually are published immediately after the meeting is held, this report is unique because there are now tangible clinical trial designs that have been funded and put into practice and the studies are being activated to accrual. Cancer 2017;123:1259-1271.

KEYWORDS:

checkpoint inhibitors; clinical trials; head and neck cancer; human papillomavirus; immunotherapy

PMID:
27906454
PMCID:
PMC5705038
DOI:
10.1002/cncr.30449
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center